Alzamend Neuro Inc
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neur… Read more
Alzamend Neuro Inc (ALZN) - Total Assets
Latest total assets as of October 2025: $5.09 Million USD
Based on the latest financial reports, Alzamend Neuro Inc (ALZN) holds total assets worth $5.09 Million USD as of October 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Alzamend Neuro Inc - Total Assets Trend (2016–2025)
This chart illustrates how Alzamend Neuro Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Alzamend Neuro Inc - Asset Composition Analysis
Current Asset Composition (April 2025)
Alzamend Neuro Inc's total assets of $5.09 Million consist of 90.8% current assets and 9.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 85.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Alzamend Neuro Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alzamend Neuro Inc's current assets represent 90.8% of total assets in 2025, an increase from 18.3% in 2016.
- Cash Position: Cash and equivalents constituted 85.8% of total assets in 2025, up from 3.7% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Alzamend Neuro Inc Competitors by Total Assets
Key competitors of Alzamend Neuro Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Alzamend Neuro Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Alzamend Neuro Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Alzamend Neuro Inc is currently not profitable relative to its asset base.
Alzamend Neuro Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.58 | 3.80 | 0.38 |
| Quick Ratio | 6.58 | 3.80 | 0.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.00 Million | $ 3.51 Million | $ -1.30 Million |
Alzamend Neuro Inc - Advanced Valuation Insights
This section examines the relationship between Alzamend Neuro Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.86 |
| Latest Market Cap to Assets Ratio | 1.53 |
| Asset Growth Rate (YoY) | 628.8% |
| Total Assets | $4.60 Million |
| Market Capitalization | $7.05 Million USD |
Valuation Analysis
Above Book Valuation: The market values Alzamend Neuro Inc's assets above their book value (1.53 x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Alzamend Neuro Inc's assets grew by 628.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Alzamend Neuro Inc (2016–2025)
The table below shows the annual total assets of Alzamend Neuro Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-04-30 | $4.60 Million | +628.80% |
| 2024-04-30 | $631.59K | -89.32% |
| 2023-04-30 | $5.92 Million | -59.25% |
| 2022-04-30 | $14.52 Million | +398.40% |
| 2021-04-30 | $2.91 Million | +60.56% |
| 2020-04-30 | $1.81 Million | +20.86% |
| 2019-04-30 | $1.50 Million | -37.88% |
| 2018-04-30 | $2.42 Million | +1726.26% |
| 2017-04-30 | $132.29K | +332.13% |
| 2016-04-30 | $30.61K | -- |